Nutri-jelly with PEITC
Dietary SupplementNutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
NCT Number: NCT03034603
This triple-blinded randomized placebo control trial aims to investigate the safety and efficacy of Nutri-PEITC jelly, a functional food, in head and neck cancer patients. The primary outcome measure includes adverse events, health-related quality of life, tumor response and progression-free survival. The secondary outcome includes serum p53 and cytochrome C levels and functional status.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
National cancer institute, Bangkok, Thailand
Previously, Nutri-jelly, a novel edible nutritious gel for patients with chewing and swallowing difficulties, was shown to be effective in improving the quality of life of head and neck cancer patients. Recently, Nutri-PEITC jelly is recently developed by addition of Phenethyl Isothiocyanate (PEITC), a phytochemical compound with chemopreventive action in animal bearing oral cancer. It intends to be a functional food for cancer survivor. The dose of PEITC in Nutri-jelly was based on safe and effective dose determined in animal studies. Furthermore, Nutri-PEITC jelly was proven safe in healthy volunteers who daily consumes for a consecutive month with no serious adverse events. The purpose of this study is to determine safety and efficacy of Nutri-jelly with PEITC in head and neck cancer patients.
independent variable: continuous Nutri -jelly with PEITC intake dependent variable (outcome): adverse effects, health-related quality of life score, tumor response, progression-free survival, serum p53 and cytochrome C levels and functional status
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
Time frame: 1 month and 3 months after receiving intervention
Evaluation of adverse events by physical examination, blood tests, and interviewing the subjects
Time frame: Baseline, 1 month and 3 months after receiving intervention
Evaluation of Health-related quality of life by using questionnaire FACT-HN
Time frame: Baseline, 1 month, 3 months after receiving intervention
Evaluation of tumor response following RECIST criteria at 1 month and 3 months
Time frame: The time of the intervention until any signs or symptoms of progressive disease be recorded.
The length of time during the intervention that the participant lives with stable disease
Time frame: 1 month and 3 months after receiving intervention
Level of both wild type and mutant p53 in serum
Time frame: 1 month and 3 months after receiving intervention
Level of cytochrome C in serum
Time frame: Baseline, 1 month and 3 months after receiving intervention
Evaluation of functional status using KPS (Karnofsky Performance Score) score
Dental Innovation Foundation Under Royal Patronage
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02395367
Head and Neck Neoplasms, Neoplasms
Beijing, Beijing Municipality, China
View Trial DetailsNCT03753932
Dental Prosthesis, Dentures
Jönköping, Sweden
View Trial DetailsNCT02460471
Head and Neck Neoplasms, Neoplasms
Montreal, Quebec, Canada
View Trial DetailsNCT04075305
Bladder Cancer, Bladder Neoplasm
Pittsburgh, Pennsylvania, United States
View Trial Details